Skip Navigation

COVID-19 Update

Due to interest in the COVID-19 vaccines, we are experiencing an extremely high call volume. Please understand that our phone lines must be clear for urgent medical care needs. We are unable to accept phone calls to schedule COVID-19 vaccinations at this time. When this changes, we will update this website. Our vaccine supply remains limited. Read all COVID-19 Vaccine Information.

Patient Care Options | Visitor Guidelines | Coronavirus Information | Self-Checker | Get Email Alerts

Chien-Fu Hung, Ph.D.

Headshot of Chien-Fu Hung
  • Associate Professor of Pathology

Research Interests

Gene therapies; cancer vaccines; ovarian cancer immunotherapy; cancer immunology ...read more

Background

Dr. Chien-Fu Hung is an associate professor of pathology and oncology and a professor of gynecology and obstetrics at the Johns Hopkins University School of Medicine. He is a member of the Johns Hopkins Kimmel Cancer Center. His research focuses on the prevention and treatment of cervical and ovarian cancers.

His team is currently using an ascitogenic ovarian/peritoneal tumor model to investigate DNA vaccine strategies encoding ovarian tumor antigens identified by microarray and SAGE.

Dr. Hung earned his Ph.D. in molecular biology from the University of Illinois. He completed a fellowship in pharmacology at the University of Pennsylvania and a fellowship in pathology at the Johns Hopkins University.

He received a Young Investigator Award from the Alliance for Cancer Gene Therapy in 2004.

...read more

Titles

  • Associate Professor of Pathology
  • Associate Professor of Gynecology and Obstetrics
  • Associate Professor of Oncology

Departments / Divisions

Centers & Institutes

Education

Degrees

  • Ph.D.; University of Illinois (Urbana-Champaign) (Illinois) (1996)

Research & Publications

Research Summary

Dr. Hung's research focuses on developing vaccination strategies for the prevention and treatment of cervical and ovarian cancers.

His lab has developed several approaches to enhance immunologic responses against different cancers. Some of these involve 

  1. targeting antigen into dendritic cells (DCs), 
  2. targeting antigen into major histocompatability class I and II processing pathways, 
  3. enhancing intercellular spreading of antigen, and 
  4. combining antigen-specific immunotherapy with agents to limit angiogenesis.

Dr. Hung's research has led to the generation of clinical-grade vaccines for HPV-associated precancerous and cancerous lesions. Of special note, two of Dr. Hung's technologies (DNA vaccines based on HSP70 and calreticulin fusion technologies) have also been licensed and are under active development by biotechnology companies. Recently, Dr. Hung's lab has utilized annexin V (AnnV) as an immune checkpoint inhibitor and tumor-homing molecule for the treatment of cancer, as AnnV greatly enhances the immunogenicity and antitumor efficacy after chemoradiation.

Additionally, Dr. Hung has developed a novel universal immunotherapeutic molecule (Alb-Flt3L) by harnessing albumin's ability to extend serum half-life and preferential trafficking towards lymph nodes as well as the properties of Flt3L to potently expand cross-presenting DCs. Alb-Flt3L enhances immunological responses mediated by cross-presenting DCs and subsequently generates potent antigen-specific T and B cell responses.

Selected Publications

Kang TH, Park JH, Yang A, Park HJ, Lee SE, Kim YS, Jang GY, Farmer E, Lam B, Park YM, Hung CF: Annexin A5 as an immune checkpoint inhibitor and tumor-homing molecule for cancer treatment. Nat Commun 2020, 11(1):1137

Kang TH, Mao CP, Kim YS, Kim TW, Yang A, Lam B, Tseng SH, Farmer E, Park YM, Hung CF: TLR9 acts as a sensor for tumor-released DNA to modulate anti-tumor immunity after chemotherapy. J Immunother Cancer 2019, 7(1):260

Tseng SH, Park ST, Lam B, Tsai YC, Cheng MA, Farmer E, Xing D, Hung CF: Novel, genetically induced mouse model that recapitulates the histological morphology and immunosuppressive tumor microenvironment of metastatic peritoneal carcinomatosis. J Immunother Cancer 2020, 8(1)

Yang PM, Hsieh YY, Du JL, Yen SC, Hung CF: Sequential Interferon beta-Cisplatin Treatment Enhances the Surface Exposure of Calreticulin in Cancer Cells via an Interferon Regulatory Factor 1-Dependent Manner. Biomolecules 2020, 10(4)

Is this you? Edit Profile
back to top button